Know Cancer

or
forgot password

Celecoxib-Mediated Inhibition of T Regulatory Cells in Human Lung Cancer


Phase 1
18 Years
N/A
Not Enrolling
Both
Non-Small-Cell Lung Carcinoma

Thank you

Trial Information

Celecoxib-Mediated Inhibition of T Regulatory Cells in Human Lung Cancer


Inclusion Criteria:



- Pathologically confirmed and surgically resectable non small cell lung cancer and
subjects must be ineligible for or refuse, neoadjuvant therapy

Exclusion Criteria:

Hypersensitivity to celecoxih or NSAIDs, previous history of GI bleeding or ulceration,
chronic or concurrent use of steroids and renal insufficiency

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science

Outcome Measure:

Measure bio-markers; safety measures

Outcome Time Frame:

2 years

Safety Issue:

No

Principal Investigator

Steven Dubinett, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

VA Greater Los Angeles Healthcare System, West LA

Authority:

United States: Federal Government

Study ID:

ONCA-043-04S

NCT ID:

NCT00108186

Start Date:

October 2004

Completion Date:

June 2011

Related Keywords:

  • Non-Small-Cell Lung Carcinoma
  • cyclooxygenase 2
  • lung cancer
  • lymphocytes
  • non small cell
  • theraputics
  • Carcinoma
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms

Name

Location

VA Greater Los Angeles Healthcare System, West LAWest Los Angeles, California  90073